C4X Discovery

Building the world's most productive drug discovery engine

Proprietary Technologies

Designing and creating best-in-class drug candidates

Small Molecule Drugs

Novel medicines across broad therapeutic areas

Target Discovery

Proprietary genetic analysis to reveal unique targets

Slide background

C4X Discovery

Building the world's most productive drug discovery engine

Slide background

Proprietary Technologies

Designing and creating best-in-class drug candidates

Slide background

Small Molecule Drugs

Novel medicines across broad therapeutic areas

Slide background

Target Discovery

Proprietary genetic analysis to reveal unique targets

Slide background

C4X Discovery

Building the world's most productive drug discovery engine

Slide background

Proprietary Technologies

Designing and creating best-in-class drug candidates

Slide background

Small Molecule Drugs

Novel medicines across broad therapeutic areas

Slide background

Target Discovery

Proprietary genetic analysis to reveal unique targets

Our Progress

Therapeutic Areas
Discovery Programmes
% Pipeline Growth - 3 year plan
4D-Structures Solved

The Pharma Letter in conversation with Dr. Clive Dix

Read More...

C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.

You must have the Adobe Flash Player installed to view this player.

C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.

UNIQUE

UNIQUE DRUG DISCOVERY ENGINE

utilising in vitro 3D shapes of drug molecules with unique software "Conformetrix" discovering more potent drugs faster

Read More

Hybrid

HYBRID BUSINESS MODEL

of wholly-owned pipeline of programmes plus partnerships with Pharma and Biotech

Read More

Management

STRENGTH OF MANAGEMENT

team with track record of value creation


Read More

Genetics

HUMAN GENETICS PLATFORM

"Taxonomy3" that provides proprietary target discovery & validation to ‘fuel’ the discovery engine

Read More

Molecules

SMALL MOLECULE DRUG

design and creation of best-in-class molecules including switch of clinically validated biologic based therapies (mAbs, peptides)

Read More

UNMET NEED

HIGH UNMET MEDICAL NEED

across multiple broad therapeutics areas to be targeted and exploited by C4XD’s cutting-edge technologies

Read More

Chief Technical Officer Dr Charles Blundell
Charles invented C4XD's core Conformetrix technology, founded C4XD and led the spin-out from The University of Manchester in 2008.
Chief Executive Officer Dr Clive Dix
Clive has over 30 years' experience in the pharmaceutical and biotechnology industries.
Chief Scientific Officer Dr Craig Fox
Craig is an experienced biologist having worked on and managed many drug discovery and development projects during the last 20 years.
Chief Executive Officer Dr Clive Dix
Clive has over 30 years' experience in the pharmaceutical and biotechnology industries.
Chief Scientific Officer Dr Craig Fox
Craig is an experienced biologist having worked on and managed many drug discovery and development projects during the last 20 years.
Chief Technical Officer Dr Charles Blundell
Charles invented C4XD's core Conformetrix technology, founded C4XD and led the spin-out from The University of Manchester in 2008.
The Company has made excellent progress with the discovery of ground-breaking molecules in recent months.
- Dr Clive Dix, Chief Executive Officer of C4XD
We are pleased to partner with C4XD and are excited about the potential of this alliance.
- Professor Chas Bountra, Chief Scientist at SGC-Oxford
We continue to expand our proprietary pipeline by using C4XD’s highly effective conformational design technology.
- Dr Charles Blundell, C4XD Chief Technology Officer